I40 I42.0 Z94.1 T86.2 E85.4 I42.1
Conditions
Interventions
Group 1: Patients included in this study will undergo an endomyocardial biopsy (EMB) as part of the clinical diagnostic workup. During this procedure, endomyocardial tissue samples are obtained for fu
Sponsors
Westdeutsches Herz- und Gefäßzentrum, Klinik für Kardiologie und Angiologie, Universitätsklinikum Essen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Indication for endomyocardial biopsy (EMB) in routine clinical practice.
Exclusion criteria
Exclusion criteria: Pregnancy, under 18 years of age.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study will be determined after completion of the endomyocardial biopsy (EMB) and subsequent data collection. The primary endpoint consists of procedure-related mortality, periprocedural arrhythmias, and pericardial effusion. Assessment of this endpoint will be based on examination findings and clinical documentation following the EMB. For this purpose, data from the procedure (EMB) and from the postprocedural echocardiography will be analyzed. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint of this study will be determined after completion of the endomyocardial biopsy (EMB). The secondary endpoint consists of newly developed acute kidney injury and vascular complications at the access site. Assessment of this endpoint will be based on examination findings and clinical documentation following the EMB. For this purpose, data from the procedure (EMB) and from postprocedural blood sampling will be analyzed. | — |
Countries
Germany
Contacts
Public ContactLars Michel
Westdeutsches Herz- und Gefäßzentrum Essen, Klinik für Kardiologie und Angiologie, Universitätsklinikum Essen
Outcome results
None listed